Diabetic retinopathy is one of the leading causes of preventable blindness, and one of the most screenable — if patients actually get screened on schedule. In practice, screening capacity is often the bottleneck: specialty reads take time, and the patients most at risk are frequently the ones least likely to complete a referral to a specialist. EYELYTIX was built to close that gap.
Where the bottleneck actually is
The clinical need for retinopathy screening is well understood; the constraint is throughput. Every image still requiring specialist review, one at a time, limits how many patients a practice can screen in a given week — and every referral a patient doesn’t complete is a missed early detection.
What AI-assisted screening changes
- Retinal images are triaged by AI at the point of capture, flagging likely disease presence before specialist review.
- Clear cases can be resolved faster, freeing specialist time for the images that genuinely need expert judgment.
- Screening can move closer to primary and specialty eye-care settings, reducing the referral step that many patients never complete.
- Every AI-assisted read is reviewed and confirmed by a qualified clinician before a result is finalized.
Built into a specialty eye-care operation
EYELYTIX doesn’t operate in isolation — it sits alongside the broader non-clinical operation we run for specialty eye-care groups, where patient coordination and scheduling already ensure the right patients are being brought in for screening in the first place. Diagnostic capacity and patient engagement have to move together, or expanding one without the other just shifts the bottleneck.
What this means for access
For specialty practices, the combination of higher screening throughput and coordinated patient engagement means more at-risk patients actually get screened, on schedule, without waiting on a stretched specialist calendar. That’s the outcome AI-assisted diagnostic screening is meant to deliver — not a faster read for its own sake, but more patients caught early.
